Agency Forms Undergoing Paperwork Reduction Act Review, 59429-59430 [2022-21187]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 189 / Friday, September 30, 2022 / Notices
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2022–21218 Filed 9–29–22; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–22–1150]
jspears on DSK121TN23PROD with NOTICES
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled ‘‘Generic
Clearance for Lyme and other Tickborne
Diseases Knowledge, Attitudes, and
Practices Surveys’’ to the Office of
Management and budget (OMB) for
review and approval. CDC previously
published a ‘‘Proposed Data Collection
Submitted for Public Comment and
Recommendations’’ notice on March 18,
2022 to obtain comments from the
public and affected agencies. CDC did
not receive comments related to the
previous notice. This notice serves to
allow an additional 30 days for public
and affected agency comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
VerDate Sep<11>2014
18:52 Sep 29, 2022
Jkt 256001
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
Lyme and other Tickborne Diseases
Knowledge, Attitudes, and Practices
Surveys (OMB Control Number 0920–
1150, Exp. 9/30/2022)—Revision—
National Center for Emerging and
Zoonotic Infectious Diseases (NCEZID),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
The Centers for Disease Control and
Prevention (CDC) Division of VectorBorne Diseases (DVBD) and other
programs working on tickborne diseases
(TBDs) are requesting a Revision to a
previously approved generic clearance
to conduct TBD prevention studies to
include knowledge, attitudes, and
practices (KAP) surveys regarding ticks
and tickborne diseases (TBDs) among
residents and businesses offering pest
control services in Lyme disease
endemic areas of the United States. The
data collection for which approval is
sought will allow DVBD to use survey
results to inform implementation of
future TBD prevention interventions.
The Revision involves a broadening of
the secondary target population from
owners and employees of pest control
companies to stakeholders of local
entities affected by TBDs (e.g., leaders in
local public health or local government;
owners or employees of pest control
companies, landscaping companies, or
other at-risk occupations; nongovernmental organizations serving atrisk populations; and/or clinicians
serving at-risk populations).
TBDs are a substantial and growing
public health problem in the United
States. From 2004–2016, over 490,000
cases of TBDs were reported to CDC,
including cases of anaplasmosis,
babesiosis, ehrlichiosis, Lyme disease,
Rocky Mountain spotted fever, and
tularemia. Lyme disease accounted for
82% of all TBDs, with over 400,000
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
59429
cases reported during this time period.
Recent studies estimate nearly 500,000
cases of Lyme disease are diagnosed
annually in the United States. In
addition, several novel tickborne
pathogens have recently been found to
cause human disease in the United
States. Factors driving the emergence of
TBDs are not well defined and current
prevention methods have been
insufficient to curb the increase in
cases. Data is lacking on how often
certain prevention measures are used by
individuals at risk, as well as what the
barriers to using certain prevention
measure are.
The primary target population for
these data collections are individuals
and their household members who are
at risk for TBDs associated with
I.scapularis ticks and who may be
exposed to these ticks residentially,
recreationally, and/or occupationally.
The secondary target population
includes stakeholders of local entities
affected by TBDs (e.g., leaders in local
public health or local government;
owners or employees of pest control
companies, landscaping companies, or
other at-risk occupations; nongovernmental organizations serving atrisk populations; and/or clinicians
serving at-risk populations) in areas
where I. scapularis ticks transmit
diseases to humans. Specifically, these
target populations include those
residing or working in the 15 highest
incidence states for Lyme disease (CT,
DE, ME, MD, MA, MN, NH, NJ, NY, PA,
RI, VT, VA, WI and WV). We anticipate
conducting one to two surveys per year,
for a maximum of six surveys conducted
over a three-year period. Depending on
the survey, we aim to enroll 500–10,000
participants per study. It is expected
that we will need to target recruitment
to about twice as many people as we
intend to enroll. Surveys may be
conducted daily, weekly, monthly, or
bi-monthly per participant for a defined
period (whether by phone or web
survey), depending on the survey or
study. The surveys will range in
duration from approximately 5–30
minutes. Each participant may be
surveyed 1–64 times in one year; this
variance is due to differences in the type
of information collected for a given
survey. Specific burden estimates for
each study and each information
collection instrument will be provided
with each individual project submitted
for OMB review. Insights gained from
KAP surveys will aid in prioritizing
which prevention methods should be
evaluated in future randomized,
controlled trials and ultimately help
target promotion of proven prevention
E:\FR\FM\30SEN1.SGM
30SEN1
59430
Federal Register / Vol. 87, No. 189 / Friday, September 30, 2022 / Notices
methods that could yield substantial
reductions in TBD incidence.
CDC requests OMB approval for an
estimated 98,830 annual burden hours.
There is no cost to respondents other
than their time to participate.
ESTIMATED ANNUALIZED BURDEN HOURS
Type of
respondent
Form name
General public, individuals or households ......
Screening instrument .....................................
Consent Form ................................................
Introductory Surveys ......................................
Monthly Surveys .............................................
Final Surveys .................................................
Daily Surveys .................................................
Stakeholder Survey ........................................
Stakeholders of local entities affected by
TBDs.
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity,Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2022–21187 Filed 9–29–22; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–22–22FI]
jspears on DSK121TN23PROD with NOTICES
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled ‘‘National HIV
Behavioral Surveillance System: Brief
HIV Bio-behavioral Assessment (NHBS–
BHBA)’’ to the Office of Management
and Budget (OMB) for review and
approval. CDC previously published a
‘‘Proposed Data Collection Submitted
for Public Comment and
Recommendations’’ notice on May 13,
2022 to obtain comments from the
public and affected agencies. CDC
received one comment related to the
previous notice. This notice serves to
allow an additional 30 days for public
and affected agency comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
VerDate Sep<11>2014
18:52 Sep 29, 2022
Jkt 256001
Number of
respondents
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
National HIV Behavioral Surveillance:
Brief HIV Bio-behavioral Assessment
(NHBS–BHBA)—New—National Center
for HIV, Viral Hepatitis, STD, and TB
Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
The purpose of National HIV
Behavioral Surveillance: Brief HIV Biobehavioral Assessment (NHBS–BHBA)
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
20,000
10,000
10,000
10,000
10,000
10,000
1,000
Number of
responses per
respondent
1
1
1
12
1
60
1
Average
burden per
response
(in hours)
15/60
20/60
30/60
15/60
30/60
5/60
30/60
is to monitor behaviors of populations at
high risk for Human Immunodeficiency
Virus (HIV) infection using mixedmethods in selected geographic areas in
the United States which lack
biobehavioral data related to HIV
transmission and prevention.
Preventing HIV, especially among
populations at high risk, is an effective
strategy for reducing individual, local,
and national healthcare costs. The
utility of this information is to provide
CDC and health department staff with
data for evaluating progress towards
state public health goals, such as
reducing new HIV infections, increasing
the use of condoms, and focusing on
populations at high risk by describing
and monitoring the HIV risk behaviors,
HIV seroprevalence and incidence, and
HIV prevention experiences of persons
at highest risk for HIV infection.
The Centers for Disease Control and
Prevention (CDC) requests a three-year
approval for a new information
collection. Data will be systematically
collected using mixed methods of
quantitative and qualitative interviews.
Brief screening interviews will be used
to determine eligibility for participation
in the quantitative and qualitative
interviews.
Project areas will conduct brief
standardized quantitative interviews
and anonymous HIV blood-based rapid
testing and supplemental testing to
those who participate in quantitative
data collection to assess HIV
seroprevalence. The data from the
quantitative interviews will provide
estimates of: (1) behavior related to the
risk of HIV and other sexually
transmitted diseases; (2) prior testing for
HIV; and (3) use of HIV prevention
services. HIV screening results will be
made available to participants, and
those with preliminary positive test
results will be linked to HIV care.
Qualitative data collection includes key
informant interviews with community
E:\FR\FM\30SEN1.SGM
30SEN1
]]>Agencies
[Federal Register Volume 87, Number 189 (Friday, September 30, 2022)]
[Notices]
[Pages 59429-59430]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-21187]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-22-1150]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled ``Generic Clearance for Lyme and other
Tickborne Diseases Knowledge, Attitudes, and Practices Surveys'' to the
Office of Management and budget (OMB) for review and approval. CDC
previously published a ``Proposed Data Collection Submitted for Public
Comment and Recommendations'' notice on March 18, 2022 to obtain
comments from the public and affected agencies. CDC did not receive
comments related to the previous notice. This notice serves to allow an
additional 30 days for public and affected agency comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570. Comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct
written comments and/or suggestions regarding the items contained in
this notice to the Attention: CDC Desk Officer, Office of Management
and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202)
395-5806. Provide written comments within 30 days of notice
publication.
Proposed Project
Lyme and other Tickborne Diseases Knowledge, Attitudes, and
Practices Surveys (OMB Control Number 0920-1150, Exp. 9/30/2022)--
Revision--National Center for Emerging and Zoonotic Infectious Diseases
(NCEZID), Centers for Disease Control and Prevention (CDC).
Background and Brief Description
The Centers for Disease Control and Prevention (CDC) Division of
Vector-Borne Diseases (DVBD) and other programs working on tickborne
diseases (TBDs) are requesting a Revision to a previously approved
generic clearance to conduct TBD prevention studies to include
knowledge, attitudes, and practices (KAP) surveys regarding ticks and
tickborne diseases (TBDs) among residents and businesses offering pest
control services in Lyme disease endemic areas of the United States.
The data collection for which approval is sought will allow DVBD to use
survey results to inform implementation of future TBD prevention
interventions. The Revision involves a broadening of the secondary
target population from owners and employees of pest control companies
to stakeholders of local entities affected by TBDs (e.g., leaders in
local public health or local government; owners or employees of pest
control companies, landscaping companies, or other at-risk occupations;
non-governmental organizations serving at-risk populations; and/or
clinicians serving at-risk populations).
TBDs are a substantial and growing public health problem in the
United States. From 2004-2016, over 490,000 cases of TBDs were reported
to CDC, including cases of anaplasmosis, babesiosis, ehrlichiosis, Lyme
disease, Rocky Mountain spotted fever, and tularemia. Lyme disease
accounted for 82% of all TBDs, with over 400,000 cases reported during
this time period. Recent studies estimate nearly 500,000 cases of Lyme
disease are diagnosed annually in the United States. In addition,
several novel tickborne pathogens have recently been found to cause
human disease in the United States. Factors driving the emergence of
TBDs are not well defined and current prevention methods have been
insufficient to curb the increase in cases. Data is lacking on how
often certain prevention measures are used by individuals at risk, as
well as what the barriers to using certain prevention measure are.
The primary target population for these data collections are
individuals and their household members who are at risk for TBDs
associated with I.scapularis ticks and who may be exposed to these
ticks residentially, recreationally, and/or occupationally. The
secondary target population includes stakeholders of local entities
affected by TBDs (e.g., leaders in local public health or local
government; owners or employees of pest control companies, landscaping
companies, or other at-risk occupations; non-governmental organizations
serving at-risk populations; and/or clinicians serving at-risk
populations) in areas where I. scapularis ticks transmit diseases to
humans. Specifically, these target populations include those residing
or working in the 15 highest incidence states for Lyme disease (CT, DE,
ME, MD, MA, MN, NH, NJ, NY, PA, RI, VT, VA, WI and WV). We anticipate
conducting one to two surveys per year, for a maximum of six surveys
conducted over a three-year period. Depending on the survey, we aim to
enroll 500-10,000 participants per study. It is expected that we will
need to target recruitment to about twice as many people as we intend
to enroll. Surveys may be conducted daily, weekly, monthly, or bi-
monthly per participant for a defined period (whether by phone or web
survey), depending on the survey or study. The surveys will range in
duration from approximately 5-30 minutes. Each participant may be
surveyed 1-64 times in one year; this variance is due to differences in
the type of information collected for a given survey. Specific burden
estimates for each study and each information collection instrument
will be provided with each individual project submitted for OMB review.
Insights gained from KAP surveys will aid in prioritizing which
prevention methods should be evaluated in future randomized, controlled
trials and ultimately help target promotion of proven prevention
[[Page 59430]]
methods that could yield substantial reductions in TBD incidence.
CDC requests OMB approval for an estimated 98,830 annual burden
hours. There is no cost to respondents other than their time to
participate.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondent Form name Number of responses per per response
respondents respondent (in hours)
----------------------------------------------------------------------------------------------------------------
General public, individuals or Screening instrument.... 20,000 1 15/60
households.
Consent Form............ 10,000 1 20/60
Introductory Surveys.... 10,000 1 30/60
Monthly Surveys......... 10,000 12 15/60
Final Surveys........... 10,000 1 30/60
Daily Surveys........... 10,000 60 5/60
Stakeholders of local entities Stakeholder Survey...... 1,000 1 30/60
affected by TBDs.
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity,Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2022-21187 Filed 9-29-22; 8:45 am]
BILLING CODE 4163-18-P
